Literature DB >> 17110163

Effects of FXR in foam-cell formation and atherosclerosis development.

Grace L Guo1, Silvia Santamarina-Fojo, Taro E Akiyama, Marcelo J A Amar, Beverly J Paigen, Bryan Brewer, Frank J Gonzalez.   

Abstract

Farnesoid X receptor (FXR), a bile-acid-activated member of the nuclear receptor superfamily, is essential in regulating bile-acid, cholesterol, and triglyceride homeostasis. Disruption of the FXR gene in mice results in a proatherosclerotic lipid profile with increased serum cholesterols and triglycerides. However, the role of FXR in foam-cell formation and atherosclerosis development remains unclear. The current study showed that the peritoneal macrophages isolated from FXR-null mice took up less oxidized LDL-cholesterol (oxLDL-C), which was accompanied by a marked reduction in CD36 expression in these cells. This result appears to be FXR-independent, as FXR was not detected in the peritoneal macrophages. To assess to what extent FXR modulates atherosclerosis development, FXR/ApoE double-null mice were generated. Female mice were used for atherosclerosis analysis. Compared to ApoE-null mice, the FXR/ApoE double-null mice were found to have less atherosclerotic lesion area in the aorta, despite a further increase in the serum cholesterols and triglycerides. Our results indicate that disruption of the FXR gene could attenuate atherosclerosis development, most likely resulting from reduced oxLDL-C uptake by macrophages. Our study cautions the use of serum lipid levels as a surrogate marker to determine the efficiency of FXR modulators in treating hyperlipidemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17110163      PMCID: PMC1751860          DOI: 10.1016/j.bbalip.2006.09.018

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  40 in total

Review 1.  Metabolism of oxidized LDL by macrophages.

Authors:  W Jessup; L Kritharides
Journal:  Curr Opin Lipidol       Date:  2000-10       Impact factor: 4.776

2.  Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime.

Authors:  Daniel Steinberg
Journal:  Nat Med       Date:  2002-11       Impact factor: 53.440

3.  Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.

Authors:  Taro E Akiyama; Shuichi Sakai; Gilles Lambert; Christopher J Nicol; Kimihiko Matsusue; Satish Pimprale; Ying-Hue Lee; Mercedes Ricote; Christopher K Glass; H Bryan Brewer; Frank J Gonzalez
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

4.  Small heterodimer partner, an orphan nuclear receptor, augments peroxisome proliferator-activated receptor gamma transactivation.

Authors:  Hitoshi Nishizawa; Kazuya Yamagata; Iichiro Shimomura; Masahiko Takahashi; Hiroshi Kuriyama; Ken Kishida; Kikuko Hotta; Hiroyuki Nagaretani; Norikazu Maeda; Morihiro Matsuda; Shinji Kihara; Tadashi Nakamura; Hidekazu Nishigori; Hideaki Tomura; David D Moore; Jun Takeda; Tohru Funahashi; Yuji Matsuzawa
Journal:  J Biol Chem       Date:  2001-11-05       Impact factor: 5.157

5.  The role of PPAR-gamma in macrophage differentiation and cholesterol uptake.

Authors:  K J Moore; E D Rosen; M L Fitzgerald; F Randow; L P Andersson; D Altshuler; D S Milstone; R M Mortensen; B M Spiegelman; M W Freeman
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

6.  ICAM-1 deficiency reduces atherosclerotic lesions in double-knockout mice (ApoE(-/-)/ICAM-1(-/-)) fed a fat or a chow diet.

Authors:  M C Bourdillon; R N Poston; C Covacho; E Chignier; G Bricca; J L McGregor
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-12       Impact factor: 8.311

7.  Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element.

Authors:  Thierry Claudel; Ekkehard Sturm; Hélène Duez; Inés Pineda Torra; Audrey Sirvent; Vladimir Kosykh; Jean-Charles Fruchart; Jean Dallongeville; Dean W Hum; Folkert Kuipers; Bart Staels
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

Review 8.  Orphan nuclear receptors find a home in the arterial wall.

Authors:  Bryan A Laffitte; Peter Tontonoz
Journal:  Curr Atheroscler Rep       Date:  2002-05       Impact factor: 5.113

9.  Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.

Authors:  C J Sinal; M Tohkin; M Miyata; J M Ward; G Lambert; F J Gonzalez
Journal:  Cell       Date:  2000-09-15       Impact factor: 41.582

10.  LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes.

Authors:  B A Laffitte; J J Repa; S B Joseph; D C Wilpitz; H R Kast; D J Mangelsdorf; P Tontonoz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-09       Impact factor: 11.205

View more
  52 in total

1.  Regulation of Macrophage Foam Cell Formation During Nitrogen Mustard (NM)-Induced Pulmonary Fibrosis by Lung Lipids.

Authors:  Alessandro Venosa; Ley Cody Smith; Alexa Murray; Tanvi Banota; Andrew J Gow; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Sci       Date:  2019-12-01       Impact factor: 4.849

Review 2.  Nuclear receptors and inflammatory diseases.

Authors:  Kun Wang; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2008-03-28

3.  Upregulation of decorin by FXR in vascular smooth muscle cells.

Authors:  Fengtian He; Qiuhong Zhang; Ramalinga Kuruba; Xiang Gao; Jiang Li; Yong Li; Wei Gong; Yu Jiang; Wen Xie; Song Li
Journal:  Biochem Biophys Res Commun       Date:  2008-06-02       Impact factor: 3.575

4.  Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: insights into the antagonism of the hypolipidemic agent Z-guggulsterone.

Authors:  Liping Yang; David Broderick; Yuan Jiang; Victor Hsu; Claudia S Maier
Journal:  Biochim Biophys Acta       Date:  2014-06-18

5.  Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis.

Authors:  Qing Wu; Lulu Sun; Xiaomin Hu; Xuemei Wang; Feng Xu; Bo Chen; Xianyi Liang; Jialin Xia; Pengcheng Wang; Daisuke Aibara; Shaofei Zhang; Guangyi Zeng; Chuyu Yun; Yu Yan; Yicheng Zhu; Michael Bustin; Shuyang Zhang; Frank J Gonzalez; Changtao Jiang
Journal:  J Clin Invest       Date:  2021-05-03       Impact factor: 14.808

Review 6.  Bile acids regulate cardiovascular function.

Authors:  Sandeep Khurana; Jean-Pierre Raufman; Thomas L Pallone
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

7.  Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice.

Authors:  Helen B Hartman; Stephen J Gardell; Chris J Petucci; Shuguang Wang; Julie A Krueger; Mark J Evans
Journal:  J Lipid Res       Date:  2009-01-27       Impact factor: 5.922

8.  Alterations of Cholesterol Metabolism in Inflammation-Induced Atherogenesis.

Authors:  David P Hajjar; Katherine A Hajjar
Journal:  J Enzymol Metab       Date:  2016-05-31

9.  Farnesoid X receptor-Acting through bile acids to treat metabolic disorders.

Authors:  Yanqiao Zhang
Journal:  Drugs Future       Date:  2010-08-01       Impact factor: 0.148

10.  Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development.

Authors:  Rengasamy R M Maran; Ann Thomas; Megan Roth; Zhonghua Sheng; Noriko Esterly; David Pinson; Xin Gao; Yawei Zhang; Vadivel Ganapathy; Frank J Gonzalez; Grace L Guo
Journal:  J Pharmacol Exp Ther       Date:  2008-11-03       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.